Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Overview Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development Chong Kun Dang Pharmaceutical Corp Kowa Co Ltd Pfizer Inc Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles CKD-508 - Drug Profile Product Description Mechanism Of Action R&D Progress CKD-519 - Drug Profile Product Description Mechanism Of Action R&D Progress dalcetrapib - Drug Profile Product Description Mechanism Of Action R&D Progress HL-16 - Drug Profile Product Description Mechanism Of Action R&D Progress K-312 - Drug Profile Product Description Mechanism Of Action R&D Progress PF-04445597 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit CETP for Dyslipidemia - Drug Profile Product Description Mechanism Of Action R&D Progress Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Products Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Product Development Milestones Featured News & Press Releases Aug 28, 2017: DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial Mar 07, 2017: DalCor's Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule Nov 10, 2016: DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib Sep 13, 2011: Study Shows Efficacy Of Imaging Technology In Evaluating Heart Disease Drug Dalcetrapib Aug 29, 2011: Roche Announces Results From Two Exploratory Phase IIb Studies Of Dalcetrapib Apr 01, 2011: Roche Announces Dalcetrapib Phase II Studies dal-VESSEL And dal-PLAQUE Show Encouraging Results Nov 18, 2009: Roche Announces Start Of New Atherosclerosis Study (dal-PLAQUE 2) For Dalcetrapib Oct 20, 2004: JT And Roche Conclude Licensing Agreement On JT's Dyslipidemia Compound Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018 Pipeline by Kowa Co Ltd, H1 2018 Pipeline by Pfizer Inc, H1 2018 Dormant Projects, H1 2018 Discontinued Products, H1 2018 Discontinued Products, H1 2018 (Contd..1), H1 2018 Discontinued Products, H1 2018 (Contd..2), H1 2018List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018